BlackRock’s Pear Therapeutics, Inc. Class A Common Stock PEAR Stock Holding History

BlackRock’s Portfolio PEAR Stock Details PEAR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-3,358,886	Closed	-$857K	–	5704
2023 Q1	$857K	Sell	3,358,886 -98,253	-3%	-$88.8K	﹤0.01%	4377
2022 Q4	$4.08M	Buy	3,457,139 +442,249	+15%	+$930K	﹤0.01%	3819
2022 Q3	$6.15M	Buy	3,014,890 +2,586,124	+603%	+$4.39M	﹤0.01%	3664
2022 Q2	$660K	Buy	428,766 +12,488	+3%	+$48.8K	﹤0.01%	4680
2022 Q1	$2.1M	Buy	+416,278	New	+$1.89M	﹤0.01%	4368

BlackRock's PEAR Position: Q2 2023 in Review

BlackRock sold out of Pear Therapeutics, Inc. Class A Common Stock (PEAR) in Q2 2023, closing a stake of 3,358,886 shares — an estimated $857K sold.

BlackRock first reported a position in PEAR in Q1 2022 and held it in 5 quarters. The position peaked at $6.15M in Q3 2022. 1 fund tracked by Wall St. Rank holds PEAR as of Q2 2023.

BlackRock reported no remaining Pear Therapeutics, Inc. Class A Common Stock position as of Q2 2023 after selling out during the quarter.
BlackRock sold 3,358,886 Pear Therapeutics, Inc. Class A Common Stock shares in Q2 2023, an estimated $857K.
BlackRock first reported a position in Pear Therapeutics, Inc. Class A Common Stock in Q1 2022 and held it in 5 quarters.
BlackRock's Pear Therapeutics, Inc. Class A Common Stock position peaked at $6.15M in Q3 2022.
1 fund tracked by Wall St. Rank held Pear Therapeutics, Inc. Class A Common Stock as of Q2 2023.

Based on BlackRock's 13F filing for Q2 2023, filed 11 Aug 2023.